Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of one-hour infusions
given once daily for 5 consecutive days in a 21-day treatment cycle; to define a recommended
phase 2 dose; and to learn more about the clinical activity of SNS-032.